Overuse of Antibiotics in Protein Supply Chains

Our collaborative investor engagement is supported by more than 70 institutional investors, representing $5.5 trillion in AUM. To protect public health and long-term value creation, the engagement asks 20 global food companies to limit the use of antibiotics in their global supply chains. This can be achieved by:

  • Establishing an antibiotics policy to phase out routine, prophylactic use across all supply chains.
  • Specifying clear targets and timelines for implementation.
  • Increasing transparency by reporting on implementation and data verification.

Latest Progress Report

The latest update to this engagement not only outlines how investors are stepping up their efforts to manage these risks but also what progress has been made on the issue from both corporate and policy-focused communities.


The use of antibiotics in protein supply chains is a leading cause of rising antimicrobial resistance (AMR) in humans. Globally, the food industry is the largest consumer of antibiotics and often uses medicines to prevent disease or promote growth in otherwise healthy farm animals.

In a recent report showing that drug-resistant infections could cost the world around US$100 trillion in lost output by 2050, the UK government described the practice as “excessive and inappropriate”.

The misuse of antibiotics presents a systemic risk to investor portfolios and public health, and this has relevance to the food, pharmaceutical, healthcare and insurance industries.

Contact: Jo Raven, Senior Manager, Research & Engagements

Related Reports

See all the briefings that the FAIRR Initiative has released on the overuse of antibiotics in protein supply chains.


Outlines investment risks linked to farm antibiotic misuse, and how investors can drive improvements in the food industry.…

14th Nov 2016 | FAIRR Initiative